a Department of Internal Medicine, School of Medicine , New York University.
b Spatial Epidemiology Lab, Department of Population Health, School of Medicine , New York University.
J Sex Res. 2019 May-Jun;56(4-5):650-658. doi: 10.1080/00224499.2018.1449190. Epub 2018 Apr 10.
Pre-exposure prophylaxis (PrEP) is an important biomedical human immunodeficiency virus (HIV) prevention tool gaining more popularity among Parisian men who have sex with men (MSM) who engage in transactional sex. This study examines the knowledge of, and willingness to use, different modalities of PrEP among this subgroup. Broadcast advertisements were placed on a geosocial-networking smartphone application with a link to a Web-based survey during three 24-hour periods in October 2016. Modified Poisson regression models were used to assess the association between engagement in transactional sex and preferences for each of these PrEP modalities. A total of 444 respondents were included. About 14% reported engagement in transactional sex. In all, 90% of MSM who engaged in transactional sex were knowledgeable of daily oral PrEP, while 13.3% were knowledgeable about long-acting injectable PrEP or penile or rectal microbicides. They were more likely to be aware of long-acting injectable PrEP (aRR = 2.52, 95% CI = 1.16 to 5.47) and willing to use daily oral PrEP (aRR = 1.48; 95% CI = 1.11 to 1.98) or long-acting injectable PrEP (aRR = 1.40; 95% CI = 1.09 to 1.81) than MSM who had not engaged in transactional sex. Long-acting injectable PrEP may be an important HIV-prevention option for MSM who engage in transactional sex if this modality is proven effective.
暴露前预防(PrEP)是一种重要的医学人类免疫缺陷病毒(HIV)预防工具,在从事商业性性行为的巴黎男男性行为者(MSM)中越来越受欢迎。本研究调查了这一亚组人群对不同 PrEP 模式的了解程度和使用意愿。2016 年 10 月,在三个 24 小时时段内,通过一款基于地理位置的社交网络智能手机应用程序发布了广播广告,并附有一个网络调查链接。使用修正泊松回归模型来评估从事商业性性行为与对每种 PrEP 模式的偏好之间的关联。共纳入 444 名受访者。约 14%的受访者报告从事商业性性行为。所有从事商业性性行为的 MSM 中,90%的人了解每日口服 PrEP,而 13.3%的人了解长效注射型 PrEP 或阴茎或直肠杀菌剂。他们更有可能了解长效注射型 PrEP(ARR=2.52,95%CI=1.16 至 5.47),并且愿意使用每日口服 PrEP(ARR=1.48;95%CI=1.11 至 1.98)或长效注射型 PrEP(ARR=1.40;95%CI=1.09 至 1.81),而未从事商业性性行为的 MSM。如果长效注射型 PrEP 被证明有效,它可能是从事商业性性行为的 MSM 的一种重要的 HIV 预防选择。